Document:

Prepared by R.R. Donnelley Financial -- Employment Letter to Timothy P. Lynch

 EXHIBIT 10.9D 
  
 Tercica Letterhead 
  
 10 September 2002 
  
 Mr. Timothy Lynch 
 1340 Lombard St. 
 Apt 1 
 San Francisco, CA 94109 
  
 Dear Tim: 
  
 Tercica is pleased to offer you a position with Tercica Medica, Inc. (the “Company”), as its Senior Vice President of Finance and Chief Financial Officer. If you decide to join us, you will receive an annual
salary of $235,000, less standard payroll deductions and all required withholdings. Your salary will be paid semi-monthly in accordance with the Company’s normal payroll procedures. You will also be entitled to participate in a Company bonus
program, if any, applicable to the Company’s executive-level employees that may be established in the future. As an employee, you will also be eligible to receive certain employee benefits, as further detailed in Exhibit A. You should
note that the Company reserves the right to modify job titles, salaries and benefits from time to time, as it deems necessary. 
  
 The Company is excited about your joining and looks forward to a beneficial and productive relationship. Nevertheless, you should be aware that your
employment with the Company is for no specified period and constitutes at-will employment. As a result, you are free to resign at any time, for any reason or for no reason. Similarly, the Company is free to conclude its employment relationship with
you at any time, with or without cause, and with or without notice. We request that, in the event of resignation, you give the Company at least two weeks notice. 
  
 In addition, if you decide to join the Company, it will be recommended at the first meeting of the Company’s Board of
Directors following your start date that the Company grant you an option to purchase 712,367 shares (which represents 1.75% of the total shares of the Company outstanding, on a fully diluted basis, including any outstanding options and warrants) of
Common Stock at $0.10 per share. In addition, it will be recommended that you will have the right to early exercise of these shares, with the Company retaining a right of repurchase of unvested shares if you leave the Company. Twenty-five percent
(25%) of the shares subject to the option shall vest 12 months after your date of employment, and the remaining shares shall vest monthly over the next 36 months in equal monthly amounts subject to your continuing employment with the Company. This
option grant shall be subject to the terms and conditions of the Company’s Stock Option Plan and Stock Option Agreement, including vesting requirements. No right to any stock is earned or accrued until such time that vesting occurs, nor does
the grant confer any right to continue vesting or employment. 

 If the Company terminates your employment without Cause and not within 12 months of a Change of Control
(as such terms are defined in the Company’s At-Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement (the “Agreement”)), then subject to your entering into and not revoking the Company’s
standard form of release of claims in favor of the Company, you will receive a severance payment equal to six (6) months of your base salary in effect at the time of termination, no additional vesting of your Stock Options will continue beyond the
date of termination, and you will have 90 days to exercise all those Options which have vested as of the date of termination. If the Company terminates your employment without Cause or you terminate your employment for Good Reason (as defined in the
Agreement) within 12 months of a Change of Control, then subject to your entering into and not revoking the Company’s standard form of release of claims in favor of the Company, you will receive a severance payment equal to six (6) months of
your base salary in effect at the time of termination, the vesting for 50% of the unvested Option shares will be accelerated as of the date of termination, and you will have 90 days to exercise all those Options which have vested. 
  
 The Company reserves the right to conduct background investigations and/or
reference checks on all of its potential employees. Your job offer, therefore, is contingent upon a clearance of such a background investigation and/or reference check, if any. 
  
 For purposes of federal immigration law, you will be required to provide to the Company documentary evidence of your
identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business days of your date of hire, or our employment relationship with you may be terminated. 
  
 We also ask that, if you have not already done so, you disclose to the
Company any and all agreements relating to your prior employment that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company’s understanding that any such agreements will
not prevent you from performing the duties of your position and you represent that such is the case. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment, occupation, consulting
or other business activity directly related to the business in which the Company is now involved or becomes involved during the term of your employment, nor will you engage in any other activities that conflict with your obligations to the Company.
Similarly, you agree not to bring any third party confidential information to the Company, including that of your former employer, and that in performing your duties for the Company you will not in any way utilize any such information. 

 
 As a Company employee, you will be expected to abide by the Company’s
rules and standards. Specifically, you will be required to sign an acknowledgment that you have read and that you understand the Company’s rules of conduct which are included in the Company Handbook, which the Company will soon complete and
distribute to you. 
  
 As a condition of your employment, you are
also required to sign and comply with the Company’s At-Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement (the “Agreement.”) The Agreement requires, among other provisions, the assignment
of patent rights to any invention made during your employment at the Company, and non-disclosure of Company proprietary information. Enclosed are two (2) copies of this Agreement, one for your 
  

 2 

 records and one for you to execute and return to the Company. Please note that we must receive your signed Agreement
before your first day of employment. 
  
 In the event of any
dispute or claim relating to or arising out of our employment relationship, you and the Company agree that (i) any and all disputes between you and the Company shall be fully and finally resolved by binding arbitration, (ii) you are waiving any and
all rights to a jury trial but all court remedies will be available in arbitration, (iii) all disputes shall be resolved by a neutral arbitrator who shall issue a written opinion, (iv) the arbitration shall provide for adequate discovery, and (v)
the Company shall pay all arbitration fees. 
  
 To accept the
Company’s offer, please sign and date this letter in the space provided below. A duplicate original is enclosed for your records. If you accept our offer, your first day of employment will be not later than 1 November 2002, or such earlier date
that is mutually acceptable to the Company and you. This letter, along with the Agreement and any agreements relating to proprietary rights between you and the Company, set forth the terms of your employment with the Company and supersede any prior
representations or agreements including, but not limited to, any representations made during your recruitment, interviews or pre-employment negotiations, whether written or oral. This letter, including, but not limited to, its at-will employment
provision, may not be modified or amended except by a written agreement signed by the Chief Executive Officer of the Company and you. This offer of employment will terminate if it is not accepted, signed and returned by 13 September 2002.

  
 We look forward to your favorable reply and to working with
you at Tercica Medica, Inc. 
  
 Sincerely, 
  
 /S/    JOHN A.
SCARLETT 

	 	

 John A. Scarlett, MD 
 President and Chief Executive Officer 
  
 Agreed to and accepted: 
  
 Signature:    /S/    TIMOTHY P. LYNCH 

	 	

  
 Printed Name:    Timothy P. Lynch 

	 	

  
 Date:    9/9/02 

	 	

  
 Enclosures 
 Duplicate Original Letter 
 Employment, Confidential Information, Invention Assignment and Arbitration Agreement 
  

 3Prepared by R.R. Donnelley Financial -- Key Employment Agreement for Howard Moore

 EXHIBIT 10.9E 
  
 TERCICA MEDICA, INC. 
  
 KEY EMPLOYEE AGREEMENT

 FOR 
 HOWARD MOORE

  
 This KEY EMPLOYEE
AGREEMENT (“Agreement”), dated as of May     , 2002 (the “Employment Date”), is entered into by and between HOWARD MOORE (“Executive”) and
TERCICA MEDICA, INC., a Delaware corporation (the “Company”). 
  
 WHEREAS, the Company desires to employ Executive to provide personal services to the Company, and wishes to provide
Executive with certain compensation and benefits in return for his services; and 
  
 WHEREAS, Executive wishes to be employed by the Company and provide personal services to the Company in return for certain compensation and benefits; 
  
 NOW, THEREFORE, in
consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows: 
  
 1.    Position, Duties and Responsibilities. 
  
 (a)    The Company will employ Executive in the position of Executive Vice
President (“EVP”). As EVP, Executive will report to the Chief Executive Officer and will perform the duties customarily associated with this position and such other duties assigned by the Company’s Board of Directors (the
“Board”). 
  
 (b)    Executive agrees to exercise the highest degree of professionalism, utilize his expertise and creative talents, and devote all of his business time and attention in performing his duties as EVP except for
(i) any outside business activities approved by the Board and (ii) periods of vacation and reasonable periods of illness or other incapacity permitted by the Company’s general employment policies. 
  
 (c) During Executive’s employment under this
Agreement, Executive shall maintain a residence in the San Francisco Bay Area and work at the Company’s headquarters. 
  
 2.    Compensation and Employee Benefits. 
  
 2.1 Base Salary, Bonuses and Benefits. 
  
 (a)    Base Salary.    Executive’s initial annual
base salary will be two hundred thousand dollars ($200,000), less standard payroll deductions and withholdings. Until the “Financing Event” (meaning financing received by the Company from investors not currently 

 
affiliated with the Company in an aggregate amount of at least $10,000,000), the Company will pay Executive, on its regular payroll schedule, a portion of
his base salary consistent with the amount of salary paid to other executive-level employees of the Company, and payment of the remainder of Executive’s base salary will be deferred. Promptly (and in any event within three business days) after
the occurrence of the Financing Event, the Company will provide payment to Executive for the total amount of his deferred base salary. Effective on the Financing Event, the Company will also commence paying Executive at his full base salary rate on
its regular payroll schedule. The Board will review Executive’s base salary at least annually, and the Board may increase (but not decrease) Executive’s salary in its discretion; provided, however, that the Company may decrease
Executive’s salary as part of a salary reduction generally applicable to the Company’s executive officers. 
  
 (b)    Bonuses.    During his employment, Executive will be entitled to participate
in a Company bonus program, if any (including bonus programs paid in the form of stock options), applicable to the Company’s executive-level employees generally that may be established in the future. 
  
 (c)    Employee
Benefits.    Executive shall be entitled to all benefits, including health and disability benefits, for which he is or may become eligible under the terms and conditions of the standard Company benefits plans which may be in
effect from time to time and provided by the Company to its employees generally. Executive shall be entitled to participate in the Company’s stock plan upon such terms as are approved by the Board, in its discretion. 
  
 (d)    Vacation
Accrual.    Executive will be entitled to vacation at a rate of five (5) weeks per year. Vacation accrual shall be limited to five (5) weeks in the aggregate. 
  
 (e)    Relocation Package.    The Company (A) will
reimburse Executive for his expenses incurred in relocating from Auckland, New Zealand to the San Francisco Bay Area, which reimbursement shall not exceed $50,000, and (B) will pay to Executive a full gross-up on any taxes that Executive is required
to pay on such reimbursement of relocation expenses (the “Relocation Package”). Executive shall be entitled to use his Relocation Package to pay for any rent, moving or home purchase expenses incurred at any time during the term of this
Agreement as a result of his personal relocation and/or his family’s relocation to the San Francisco Bay Area. 
  
 (f)    Other Benefits.    Within ten (10) days after the initial closing of the
Company’s Series A round of financing, the Company shall pay Executive a bonus in the amount of $26,400. 
  
 2.2    Stock Option Grant.    Within 30 days following the closing of the first Financing
Event, the Company will grant Executive a stock option (the “Option”) to purchase 75,000 shares of the Company’s Common Stock. The exercise price per share of the Option will be equal to the fair market value of the Company’s
Common Stock on the date of the grant as determined by the Board. The Option will be subject to the following vesting schedule: as long as Executive remains employed by the Company at such times, twenty-five percent (25%) of the Option shares will
be vested and immediately exercisable upon the first anniversary of the date of grant, and the remaining Option shares will vest in thirty-six (36) equal monthly installments 

  

 2 

 
thereafter, so as to be one hundred percent (100%) vested on the four (4) year anniversary of the date of Option grant; provided, however, if
(A) on the second anniversary of the date of this Agreement, Executive is still employed by the Company, or (B) prior to the second anniversary of the date of this Agreement, Executive’s employment is terminated by the Company without Cause (as
defined in Section 3(e)) or by Executive for Good Reason (as defined in Section 3(f)), then in either case the vesting schedule of the Option shall accelerate so that all Option shares that have not previously vested shall vest immediately upon such
termination. 
  
 3.    Term of
Employment; Termination. 
  
 (a)    Definition of Change in Control.    For purposes of this Agreement, the term “Change of Control” means the consummation of any of the following transactions: 

 
 (1) the stockholders of the Company approve a
business combination (such as a merger or consolidation) of the Company with any other corporation or other type of business entity (such as a limited liability company), other than a business combination which would result in the voting securities
of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) at least fifty percent (50%) of the total voting power represented by
the voting securities of the Company or such controlling surviving entity outstanding immediately after such business combination; provided, however, that a Financing Event shall not constitute a Change of Control; or 
  
 (2) the sale, lease, exchange or other transfer or
disposition by the Company of all or substantially all of the Company’s assets by value. 
  
 (b)    Parachute Payments.    If any payment or benefit Executive would receive
pursuant to a Change in Control from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”), and
(ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be reduced to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest
portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal,
state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater amount of the Payment. If a reduction in payments
or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order unless Executive elects in writing a different order: reduction of cash payments;
cancellation of accelerated vesting of stock awards; reduction of employee benefits. In the event that acceleration of vesting of stock award compensation is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the
date of grant of Executive’s stock awards unless Executive elects in writing a different order for cancellation. 
  
 (1)    The accounting firm engaged by the Company for general audit purposes as of the day prior to the
effective date of the Change in Control shall perform the 

  

 3 

 
foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting
the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be
made hereunder. 
  
 (2)    The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar
days after the date on which Executive’s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the accounting firm determines that no Excise Tax
is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such
Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive. 
  
 (c)    Term of Employment.    This Agreement will become effective as of the first
date set forth above, and will remain in effect for a period of two (2) years unless terminated as specified herein. Executive’s employment will be at-will and, subject to the terms of this Agreement, either Executive or the Company may
terminate the employment relationship at any time upon notice to the other, with or without Cause (defined herein), Good Reason (defined herein), or advance notice. 
  
 (d)    Severance Benefits For Termination Without Cause or Resignation for
Good Reason.    If, prior to the second anniversary of the date of this Agreement, the Company terminates Executive’s employment without Cause (defined in Section 3(e)) or Executive resigns his employment for Good Reason
(defined in Section 3(f)), Executive shall receive the following severance benefits from the Company (collectively, the “Severance Benefits”): (i) at Executive’s sole election, Executive will either continue to receive his annual base
salary in effect as of the termination effective date (or, if Executive resigns his employment pursuant to Section 3(f)(ii), he will receive payments equal to his base salary in effect prior to the reduction in his compensation leading to his
resignation), subject to standard payroll deductions and withholdings, on the Company’s standard payroll dates for the period from the termination effective date and continuing for six months (or, if more than 18 months have elapsed since the
date of this Agreement, continuing for that number of months that equals 24 months less the number of months that have elapsed) thereafter, or, within five (5) business days following the termination effective date, he will receive a lump sum
severance payment equal to six (6) months (or, if more than 18 months have elapsed since the date of this Agreement, equal to that number of months that equals 24 months less the number of months that have elapsed) of his base salary in effect as of
the termination effective date (or, if Executive resigns his employment pursuant to Section 3(f)(ii), he will receive a severance payment equal to six (6) months (or, if more than 18 months have elapsed since the date of this Agreement, equal to
that number of months that equals 24 months less the number of months that have elapsed) of his base salary in effect prior to the reduction in his compensation leading to his resignation), subject to standard payroll deductions and withholdings;
(ii) the unvested portions of any and all of Executive’s stock option grants or other equity grants will vest in the manner set forth in Section 2.2; and (iii) if Executive 

  

 4 

 
timely elects to continue his Company-provided group health insurance coverage pursuant to federal COBRA law, the Company will reimburse him for the cost of
his COBRA premiums to continue his health insurance coverage for him and his dependents (if applicable) for six (6) months (or, if more than 18 months have elapsed since the date of this Agreement, for that number of months that equals 24 months
less the number of months that have elapsed) following the termination effective date. 
  
 (e)    Definition of Cause for Termination.    For purposes of this Agreement,
“Cause” for termination means: (i) Executive’s conviction of any felony; (ii) Executive’s participation in any fraud or act of dishonesty against the Company resulting in material damage to the Company; (iii) Executive’s
material breach of this Agreement or his Proprietary Information and Inventions Agreement; or (iv) other wrongful conduct by Executive that in the good faith and reasonable determination of the Board demonstrates Executive’s gross unfitness to
serve, provided that Executive is given at least thirty (30) days advance written notice of such conduct and a reasonable opportunity to cure. 
  
 (f)    Definition of Resignation for Good Reason.    For purposes of this Agreement,
“Good Reason” for resignation “Good Reason” shall mean, without Executive’s express written consent (i) a significant reduction of Executive’s duties, position or responsibilities relative to Executive’s duties,
position or responsibilities in effect immediately prior to such reduction; provided, however, that a reduction in duties, position or responsibilities solely by virtue of the Company being acquired and made part of a larger entity (as, for example,
when, following a Change of Control, the Chief Technical Officer of the Company remains the Chief Technical Officer of a division or subsidiary of the acquirer that contains the Company’s business) shall not constitute a “Good
Reason”; (ii) a reduction by the Company of Executive’s base salary as in effect immediately prior to such reduction (except as part of a base salary reduction generally applicable to executives); (iii) a material reduction by the Company
in the kind or level of employee benefits to which Executive is entitled immediately prior to such reduction with the result that Executive’s overall benefits package is significantly reduced (except as part of a reduction generally applicable
to executives); or (iv) a relocation of the Company’s headquarters to a site more than 50 miles from the San Francisco Bay Area; provided, however, that the Company shall have a period of thirty (30) days following receipt of written notice
from Executive specifying the grounds for a purported voluntary termination for Good Reason to cure any event or failure that would otherwise constitute Good Reason. 
  
 4.    Other Activities During Employment. 
  
 (a)    Except as permitted by
Section 4(b) below, during Executive’s employment he agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by Executive to be adverse or antagonistic to the Company, or its business
or prospects, financial or otherwise. 
  
 (b)    During the term of Executive’s employment by the Company except on behalf of the Company, Executive will not directly or indirectly, whether as an officer, director, stockholder, partner, proprietor,
associate, representative, consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection with any other person, corporation, firm, partnership or other entity whatsoever that

  

 5 

 
is a competitor of the Company (a “Competing Business”); provided, however, that anything above to the contrary notwithstanding, Executive
may own, as a passive investor, securities of any Competing Business, as long as his direct holdings in any one such corporation do not in the aggregate constitute more than one percent (1%) of the voting stock of such corporation. 
  
 5.    Former Employment. 
  
 (a)    Executive represents and
warrants that his employment by the Company will not conflict with and will not be constrained by any prior employment or consulting agreement or relationship. Executive represents and warrants that he does not possess confidential information
arising out of prior employment which, in his best judgment, would be utilized in connection with his employment by the Company, except in accordance with agreements between Executive’s former employer and the Company. 
  
 (b)    If, in spite of the second
sentence of Section 5(a), Executive should find that confidential information belonging to any former employer might be usable in connection with the Company’s business, he will not disclose to the Company or use on behalf of the Company any
confidential information belonging to any of his former employers (except in accordance with agreements between the Company and any such former employer); but during his employment by the Company, Executive will use in the performance of his duties
all information which is generally known and used by persons with training and experience comparable to his own and all information which is common knowledge in the industry or otherwise legally in the public domain. 
  
 6.    Indemnification of
Executive.    The Company shall indemnify Executive for his conduct as a member of the Company’s Board of Directors and as the Company’s EVP to the fullest extent allowed by applicable law. Without limiting the
foregoing, Executive shall be entitled to the benefit of the indemnification provisions contained on the date hereof in the Bylaws of the Company. 
  
 7.    Restrictions on Equity Transfers. 
  
 (a)    Investors’ Rights Agreement.    Executive
understands that the Company intends to enter into investor rights agreements or investors’ rights agreement (collectively, “Investors’ Rights Agreements”) with certain of its investors, including Genentech, Inc. (collectively,
the “Investors”), pursuant to which the Company will agree to place certain transfer restrictions on Executive’s equity securities in the Company. Accordingly, Executive agrees not to dispose of any shares of the Company’s Common
Stock owned by him (unless the Board, including a majority of the Series A Directors (as that term is used in the Investors’ Rights Agreements), consents to the proposed transfer), until the earliest to occur of the following: (i) there remain
outstanding less than 10,000,000 shares of the Series A Preferred Stock purchased by the Investors; (ii) the closing of the Company’s first firm commitment underwritten public offering pursuant to an effective registration statement filed by
the Company under the Securities Act of 1933, as amended; (iii) the closing of any liquidation, dissolution, or winding up of the Company whether voluntary or involuntary including any sale, exchange, conveyance or other disposition of the capital
stock of the Company in a transaction or series of related transactions in which more than fifty percent (50%) of the voting power of the Company 
  

 6 

 
is disposed of, or the sale of all or substantially all of the Company’s assets; and (iv) the eighth anniversary of the first closing of sales of the
Company’s Series A Preferred Stock to the Investors. If the relevant provisions of the Investors’ Rights Agreements, as executed, differ from the foregoing provisions of this Section 7(a), this Section 7(a) shall be similarly revised.

  
 (b)    ROFR and
Co-Sale Agreement.    Executive understands that the Company intends to enter into a right of first refusal and co-sale agreement (the “ROFR and Co-Sale Agreement”) with certain of its investors, which agreement may
place certain transfer restrictions on Executive’s equity securities in the Company. Such transfer restrictions may include (i) a right of first refusal in favor of the Company and certain of its investors to purchase Executive’s equity
securities in the Company before such equity securities may be sold to third parties and (ii) a co-sale right in favor of certain of the Company’s investors to participate in any proposed sales to third parties of Executive’s equity
securities in the Company. Executive hereby agrees to be bound by such provisions of the ROFR and Co-Sale Agreement as a “Restricted Party” thereunder. 
  
 8.    No Offsets or Mitigation.    Unless otherwise expressly provided
herein, no payment of salary, bonus or Severance Benefits pursuant to this Agreement shall reduce any other payment or benefit to which Executive is otherwise entitled except pursuant to the express terms under which such other payment or benefit is
provided, nor shall a payment or benefit provided other than under this Agreement reduce payment of salary, bonus or Severance Benefit under this Agreement except pursuant to the express terms of this Agreement. The Company shall not offset against
any payment of salary, bonus or Severance Benefits under this Agreement or against any stock or stock option grants and the securities receivable thereunder the amount of any claims it or any affiliated entity may have against Executive, including,
without limitation, any claims under this Agreement. Payment of salary, bonus and Severance Benefits pursuant to this Agreement, and Executive’s exercise of any stock option grants and his receipt of securities thereunder shall not require
Executive to mitigate the amount of such payment or receipt by seeking other employment or otherwise. 
  
 9.    Authorization for Agreement; Absence of Conflicts.    The Company hereby represents that the
person executing this Agreement has been duly authorized by the Board to execute this Agreement on its behalf and that this Agreement is a valid, binding and enforceable agreement and not in conflict with any other agreement to which the Company is
a party. Except as noted herein, all consents and approvals necessary for the Company to enter into this Agreement have been obtained. There are no conflicts between this Agreement and any laws to which the Company is subject or the Company’s
Certificate of Incorporation or Bylaws. 
  
 10.    Waiver.    If either party should waive any breach of any provisions of this Agreement, he or it will not thereby be deemed to have waived any preceding or succeeding breach of
the same or any other provision of this Agreement. 
  
 11.    Headings.    The headings of the sections hereof are inserted for convenience only and will not be deemed to constitute a part hereof nor to affect the meaning thereof.

  
 12.    Amendment.    This Agreement may not be amended or modified except by a written instrument signed by Executive and a duly authorized member of the Board. 
  

 7 

 13.    Severability.    If any provision of this
Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement, and the Agreement should be enforced insofar as possible to achieve the intent of the parties.

  
 14.    Right to
Work.    As required by law, this Agreement is subject to satisfactory proof of Executive’s right to work in the United States. 
  
 15.    Governing Law.    This Agreement will be construed and interpreted in accordance with the
laws of the State of California. 
  
 16.    Complete Agreement.    This Agreement, together with the ROFR and Co-Sale Agreement, constitutes the complete, final and exclusive embodiment of Executive’s employment
agreement with the Company. This Agreement is entered into without reliance upon any promise, warranty or representation, written or oral, other than those expressly contained herein, and supersedes any other such promises, warranties,
representations or agreements, including without limitation any employment agreement between Executive and Tercica Limited, a New Zealand limited liability company. 
  
 IN WITNESS WHEREOF, the parties have executed this
Agreement on the day and year written below. 
  

	TERCICA MEDICA, INC.
		
	By:	 	/s/ John A. Scarlett
	 	

		
	Name:	 	John A. Scarlett
	 	

		
	Title:	 	President/CEO
	 	

  
 Accepted and agreed: 

 
 /s/ Howard
Moore                         
 HOWARD MOORE 
  

 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]